KDM4A and myocardial infarction: In addition, we confirmed that ML324,[50] a small‐molecule inhibitor of Kdm4a, suppresses interstitial fibrosis in the border zone after MI, indicating that ML324 shows promise for treating cardiac fibrosis in clinical practice.